

Technology Appraisal Committee A Interests Register

Topic: Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

Publication Date: 21 May 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Steve Edwards	TAC A Committee Member	Direct Professional	Steve is the director of the EAG for ID6317.	06/05/2025 04/02/2025	It was agreed that Steve's declaration would prevent him from participating in discussions on this appraisal.
Patrick De Barr	TAC A Committee Member	Indirect: Financial	Patrick works for GSK who have a treatment approved in endometrial cancer in the CDF	04/02/2025	It was agreed that Patrick's declaration would prevent him from participating in discussions on this appraisal.
Becky Pennington	TAC A Committee Member	Indirect: Financial	Becky's employer (University of Sheffield) receives income from olaparib.	05/02/2025	It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal.
James Fotheringham	TAC A Committee Member	Indirect: Financial	AstraZeneca - I have performed/supported systematic reviews on hypertension, paid to my employer.	06/02/2025	It was agreed that James' declaration would not prevent him from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
					participating in discussions on this appraisal.
Dominic Pivonka	TAC A Committee Member	Indirect: Financial	Dominic's employer (AbbVie) has a treatment being evaluated for endometrial cancer in phase 1	12/02/2025	It was agreed that Dominic's declaration would not prevent him from participating in discussions on this appraisal.
Stella O'Brien	TAC C Committee Member	Indirect: Non-Financial	Stella is a member of NHS England's Genomics: Cancer Working Group. She considers additions to the National Genomic Test Directory and the workflow for Genomic Laboratory Hubs. She does not receive any honoraria or other direct/indirect reward for this activity.	03/03/2025	It was agreed that Stella's declaration would not prevent her from participating in discussions on this appraisal.
Gemma Eminowicz	Clinical Expert	Direct: Financial	Consulting and advisory board fees from MSD, Eisai and GSK: GSK Advisory boards – April and June 2024 Consultancy contract with MSD started October 2023 working on real world endometrial cancer data	04/03/2025	It was agreed that Gemma's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>and PRO reporting. Total income in past 1 year £652.40.</p> <p>MSD advisory board July 2024 on first line advanced endometrial cancer treatment and role of pembrolizumab/dostarlimab – fee to be paid £1344</p> <p>Consultancy contract with Eisai started focusing on information leaflet production etc</p>		
Dr John McGrane	Clinical Expert	Direct - Financial	<p>Travel Grant: Tesaro (GSK), BMS</p> <p>Speaking Honoraria: GSK, BMS, MSD, Eisai</p> <p>Advisory Board: AstraZeneca, GSK, BMS, MSD, Eisai</p>	04/03/2025	It was agreed that Dr McGrane's declaration would not prevent him from providing expert advice to the committee.